ZAI LAB
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the C... hinese market. Leveraging their teamโs extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partnerโs and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.
ZAI LAB
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.zailaboratory.com
Total Employee:
1001+
Status:
Active
Contact:
+86 21 6163 2588
Email Addresses:
[email protected]
Total Funding:
2.01 B USD
Technology used in webpage:
Domain Not Resolving Font Awesome IPv6 Google Universal Analytics Microsoft IIS 10 PHP 7 Amazon Route 53 ASP.NET 4.0 Microsoft Azure
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
I-Mab Biopharma
I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Insilico Medicine
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Ocon Healthcare
Our mission is to introduce innovative, high-quality an intrauterine drug-delivery technology to improve womenโs health and quality of life
PharmNovo
PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe.
ROME Therapeutics
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
SAI Life Sciences
SAI Life Sciences delivers advanced Discovery, Contract Development and Manufacturing Solutions.
WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Vivo Capital
Vivo Capital investment in Series C - Zai Lab
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Zai Lab
OrbiMed
OrbiMed investment in Series C - Zai Lab
Rock Springs Capital
Rock Springs Capital investment in Series C - Zai Lab
Qiming Venture Partners
Qiming Venture Partners investment in Series C - Zai Lab
Sequoia Capital China
Sequoia Capital China investment in Series B - Zai Lab
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Zai Lab
OrbiMed
OrbiMed investment in Series B - Zai Lab
Advantech Capital
Advantech Capital investment in Series B - Zai Lab
TF Capital
TF Capital investment in Series B - Zai Lab
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2016-12-01 | dMed | Zai Lab investment in Series A - dMed | 8 M USD |
Key Employee Changes
Date | New article |
---|---|
2023-07-06 | Zai Lab promotes Yajing Chen to CFO, succeeding Billy Cho |
2022-11-08 | Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer |
Official Site Inspections
http://www.zailaboratory.com Semrush global rank: 2.91 M Semrush visits lastest month: 5.51 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zai Lab"
About Zai Lab - Zai Lab
Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, autoimmune โฆSee details»
What We Do - Zai Lab
Our strengths are the global experience within our organization in innovative drug R&D, our broad product portfolio and pipeline, and our track record of execution with speed and quality in clinical development, regulatory review, and โฆSee details»
Investor Overview โ Zai Lab Limited
2 days ago [email protected]. Lina Zhang, VP, Corporate Strategy and Capital Markets [email protected]. Media Inquiries Shaun Maccoun, Executive Director, Global Communications +1 (415) 317 โฆSee details»
Zai Lab - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +86 21 6163 2588 Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious โฆSee details»
Zai Lab - LinkedIn
Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing โฆSee details»
ZAI Lab Company Profile - Office Locations, Competitors ... - Craft
Oct 28, 2024 ZAI Lab has 5 employees across 7 locations and $266.72 m in annual revenue in FY 2023. See insights on ZAI Lab including office locations, competitors, revenue, financials, โฆSee details»
Zai Lab Announces Third Quarter 2024 Financial Results and โฆ
Sep 30, 2024 Strong growth in net product revenue of 47% y-o-y to reach $101.8 million for the third quarter of 2024 Positive China bridging study of KarXT in schizophrenia; expected โฆSee details»
10 Years of Excellence - Zai Lab
Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company.See details»
Zai Lab Announces the Appointment of Josh Smiley as Chief โฆ
Mar 15, 2022 Mr. Smiley began his career at Lilly in 1995, holding leadership positions across the organization culminating in his most recent role of Senior Vice President and Chief โฆSee details»
Zai Lab - Overview, News & Similar companies | ZoomInfo.com
May 12, 2024 www.zailaboratory.com. Revenue $291.1 Million. Stock Symbol ZLAB. Industry Medical Devices & Equipment Manufacturing . Most Recent Scoops. May 13 2024. Earnings. โฆSee details»
Zai Lab Announces Second Quarter 2024 Financial Results and โฆ
Nov 27, 2024 Our efforts to build a stronger and more efficient organization, coupled with our innovative pipeline, position us for substantial topline growth and set us on the path to achieve โฆSee details»
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel ...
Nov 21, 2024 SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2024-- Zai Lab (โZai Labโ, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (โPfizerโ, NYSE: PFE) announced today โฆSee details»
Zai Lab - LinkedIn
Zai Lab | 25,206 followers on LinkedIn. Delivering innovative, transformational outcomes to patients around the world | Zai Lab is an innovative, commercial-stage biopharmaceutical โฆSee details»
Position Statements - Zai Lab
International Organization for Standardization (ISO) Supplier C ode of Conduct. Occupational Health and Safety Position Statement. U.S. Green Building Council (GBC) Zai Lab 2022 ESG โฆSee details»
Zai Lab Announces First Quarter 2022 Financial ... - Zai Lab Limited
May 10, 2022 Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET. SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 10, 2022 (GLOBE โฆSee details»
Zai Lab: Positioned For Growth In The Oncology Treatment Market
Ir.zailaboratory.com R&D expenses for 2022 saw a decrease when compared to the prior year. The reasoning behind this is lower upfront payments made for new licenses, indicating that the โฆSee details»
Sustainability - Zai Lab
We commit to a healthier, more sustainable future. At Zai Lab, we understand and appreciate Environmental Protection, Social Responsibility and Corporate Governance (ESG) matters for โฆSee details»
Zai Lab Announces Second Quarter 2021 Financial ... - Zai Lab โฆ
Aug 9, 2021 Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT SHANGHAI and SAN FRANCISCO , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Zai Lab โฆSee details»
Zai Lab Presents Positive Results from Phase 3 PRIME ... - Zai Lab โฆ
Mar 20, 2022 PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study โฆSee details»